Medilink East Midlands member Novozymes has announced that it has separated its biopharma activities into an independent company called Albumedix.
Albumedix will continue to develop its market leading position within recombinant albumin-based products and technologies. Albumin is a naturally occuring protein that can be found in human blood.
Albumedix will be headquartered in Lyngby, Denmark, with R&D and production facilities in Nottingham, UK. Novozymes retains full ownership of Albumedix, and the newly created company will employ approximately 100 people.
To read the full story, please click here.
